Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
8.31
0.00 (0.00%)
Apr 27, 2026, 1:17 PM EDT - Market open
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 28, which predicts a 236.95% increase from the current stock price of 8.31.
Price Target: $28 (+236.95%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Xilio Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $28 | Buy | Initiates | $28 | +236.95% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $84 → $56 | Buy | Maintains | $84 → $56 | +573.89% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $98 | Strong Buy | Reiterates | $98 | +1,079.32% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $98 | Strong Buy | Reiterates | $98 | +1,079.32% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $280 → $140 | Buy | Maintains | $280 → $140 | +1,584.74% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
27.58M
from 43.77M
Decreased by -36.98%
Revenue Next Year
74.13M
from 27.58M
Increased by 168.77%
EPS This Year
-2.55
from -7.73
EPS Next Year
-6.79
from -2.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 28.7M | 77.1M | ||||||
| Avg | 27.6M | 74.1M | ||||||
| Low | 26.8M | 71.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -34.5% | 179.4% | ||||||
| Avg | -37.0% | 168.8% | ||||||
| Low | -38.8% | 160.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.65 | -7.06 | |
| Avg | -2.55 | -6.79 | |
| Low | -2.47 | -6.59 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.